Life Sciences Experts to Explore Global Collaboration, AI, and Clinical Trial Innovation at DIA Canada Annual Meeting The upcoming DIA Canada Annual Meeting, taking place on November 14-15 in Gatineau, Quebec, will gather life sciences leaders to discuss Canada’s precision…
Clarametyx Biosciences Moves Forward with Phase 2a Study of CMTX-101 for Cystic Fibrosis Infections Clarametyx Biosciences, Inc. has successfully completed the Phase 1b portion of its clinical trial for CMTX-101, a novel immune-enabling antibody therapy aimed at treating pulmonary infections…
Kezar Life Sciences Updates on Clinical Trials for Zetomipzomib Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases, has provided important updates on its clinical trials. The Independent Data Monitoring Committee (IDMC)…
Evernorth and Transcarent Collaborate to Deliver Unmatched Cancer Care, Navigation, and Support Services Starting January 1, 2025 Transcarent, known as the One Place for Health and Care, has been selected to power Evernorth Health Services’ new Oncology Benefit Services program.…
Over 50 Research Studies by IVI RMA North America Set to Advance Infertility Care at ASRM 2024 IVI RMA North America, which encompasses Reproductive Medicine Associates and Boston IVF, will showcase more than 50 groundbreaking infertility research studies at the…
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative therapies for seizure disorders, has shared new data from its Phase 3 RAISE trial on intravenous (IV) ganaxolone for refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS)…
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and the Usuki City Medical Association have demonstrated that blood biomarkers can effectively predict amyloid beta (Aβ) accumulation in the brain, a major factor linked to Alzheimer’s disease. Their findings come from a…
Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for treating seriously ill adult patients with Gram-negative (GN) bacterial infections.…
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM) held in Prague…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and COVID-19 at IDWeek 2024,…
Etcembly and University of Surrey Launch Study to Transform Cancer Treatment British techbio innovator Etcembly is collaborating with researchers from the University of Surrey to launch a groundbreaking study aimed at revolutionizing cancer treatment. The research will analyze the immune…
STRIDE-8 Study Results Highlight CAPVAXIVE’s Efficacy in Pneumococcal Disease Prevention CAPVAXIVE Demonstrates Strong Immune Response and Coverage Against Major Serotypes RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, presented promising results from the…